Sector News

Sanofi to add 350 jobs at shared services site in Hungary

October 4, 2019
Life sciences

Get involved in the discussion! Click here to comment on this story

Sanofi may be trimming its headcount in Japan through voluntary retirements, but the drugmaker is adding jobs in Hungary. The company plans to open a shared services center in Budapest and employ 350 people there.

The site will start with 100 workers and provide business support services such as accounting, finance and human resources in seven languages, according to a press release (PDF). Sanofi currently employs more than 2,000 people in Hungary at three manufacturing plants, a logistics site and a global strategic unit. The company plans to grow employment to 350 by 2022.

The news comes right on the heels of Sanofi’s confirmation that it’s trimming jobs in Japan through voluntary early retirements, although the drugmaker didn’t confirm a target number of job cuts. Citing a source, Reuters reported the company wants to reduce its headcount by 200 employees in the country.

It also comes amid CEO Paul Hudson’s “listening tour,” during which he’s working to learn as much as he can about the company by visiting numerous sites and countries. Hudson joined from Novartis last month and hasn’t yet talked about future strategies, but he plans to have a presentation ready for an investor event in December.

Before the Japan retirement confirmation, Sanofi in June said it would cut 466 jobs in its R&D group in France and Germany. In April, the company said it would lay off an undisclosed number of U.S. sales staffers.

Meanwhile, the company is weighing strategic options in Bangladesh, a spokesman confirmed. Local reports have said the company intends to sell its share and exit the country, creating uncertainty for 1,000 workers.

Sanofi operates in more than 100 countries and employed 104,266 workers at the end of the year, down slightly from 106,566 at the end of 2017 and 106,859 at the end of 2016.

By Eric Sagonowsky

Source: Fierce Pharma

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 19, 2019

Big Data is the ‘next frontier’ for medicine, says Dexcom CEO

Life sciences

LinkedIn Twitter FacebookThe health care industry will continue to be transformed by the role of Big Data, DexCom CEO Kevin Sayer told CNBC’s Jim Cramer on Wednesday. “This whole integration […]

November 19, 2019

Aerie Pharmaceuticals agrees to acquire Avizorex Pharma

Life sciences

LinkedIn Twitter FacebookAerie Pharmaceuticals, an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other […]

November 18, 2019

Bristol-Myers’ $74B Celgene buy wins antitrust nod in FTC party-line split vote

Life sciences

LinkedIn Twitter FacebookIndustry watchers largely expected that Bristol-Myers Squibb and Celgene would win U.S. antitrust clearance for their $74 billion merger. But what’s perhaps unexpected is that the permission was […]

Subscribe to our Weekly Newsletter

We're easy to reach